Vyxeos
Prescribing
Information (PI) PI
  • THE PATIENTS
  • THE FORMULATION
  • THE DATA
  • THE DOSING
  • THE RESOURCES
  • SmPC
  • PI
The formulation

Vyxeos Liposomal is the first dual-drug advanced liposomal formulation1

Optimising the delivery of daunorubicin and cytarabine1,2

the formulation

Mechanism of action

play
the formulation
Synergistic ratio

Synergistic ratio

Fixed 1:5 molar ratio of daunorubicin and cytarabine has been shown to produce a synergistic effect in vitro3

High concentration

High concentration

Liposomes accumulate and persist in the bone marrow in high concentrations, as shown in animal models4

Prolonged delivery

Prolonged delivery

Synergistic molar ratio maintained for a prolonged period of time – over 24 hours after administration1,4

Preferential uptake

Preferential uptake

Vyxeos Liposomal is preferentially taken up by leukaemia cells vs normal bone marrow cells, as shown in vitro2,4

This website is intended for European Healthcare Professionals only.
REFERENCES
  • Tolcher AW, Mayer LD. Future Oncol 2018;14(13):1317-32.
  • Lancet JE et al. J Clin Oncol 2018;36(26):2684-92.
  • Dicko A et al. Expert Opin Drug Deliv 2010;7(12):1329-41.
  • Vyxeos Liposomal. European Summary of Product Characteristics.

ADVERSE EVENTS REPORTING

Adverse events should be reported. Healthcare professionals are asked to report any adverse events via their national reporting system (see Section 4.8 of SmPC). Adverse events should also be reported to Jazz Pharmaceuticals by email to medinfo-int@jazzpharma.com or phone via +353 1 968 1631 (may include an international call charge).

Job code: INT-VYX-2200141
Date of Preparation: September 2022
Vyxeos
Vyxeos
  • Contact Us
  • Terms of
    Use
  • Privacy
    Statement
  • Cookie
    Policy
  • Prescribing
    Information (PI)
You are being directed to the Jazz corporate website.

Follow link
You are being directed to an external website.
Follow link
This Jazz Pharmaceuticals website has been created for healthcare professionals only.

Important notice: This site has been created for healthcare professionals only. By entering this site, you are confirming that you are a European healthcare professional. This site contains promotional information.

I CONFIRM THAT I AM A EUROPEAN HEALTHCARE PROFESSIONAL

I AM A UK HEALTHCARE PROFESSIONAL

I AM A US HEALTHCARE PROFESSIONAL

I AM NOT A HEALTHCARE PROFESSIONAL
You are leaving the vyxeos.eu website.

Please note that this information is intended for healthcare professionals in the UK

https://vyxeos.co.uk
You are leaving the vyxeos.eu website.

Please note that this information is intended for healthcare professionals in the US only

https://vyxeospro.com
For European patients and the general public

For more information:

Patient information leaflet
EMA - Information on Vyxeos Liposomal

By clicking here you will be taken to the European Medicines Agency’s external website

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly through your national medicines side effect reporting system or to Jazz Pharmaceuticals AEreporting@jazzpharma.com. By reporting side effects, you can help provide more information on the safety of this medicine.